The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

Alternative therapies, like medical cannabis, may help people manage their seizures better. They can be included alongside your normal treatment plan.

UCB’s continued commitment to leading research aimed at improving treatment outcomes for people living with neurological conditions.Data include the use of FINTEPLA®▼ (fenfluramine)1 in Dravet ...

New research reveals that soaring heat can overwhelm the brain’s delicate balance, leading to a surge in seizure activity and ...

Dr Ray O’Connor takes a look at the latest clinical articles on the subject of epilepsy, a common neurological disease that affects one to two per cent of the general population ...

While Harmony Biosciences HRMY may not be a typical cannabis stock involved in cultivation, processing, or sales of marijuana ...

Jazz Pharmaceuticals plc is a Buy with its robust portfolio, potential FDA approvals, and innovative oncology treatments.

Bexicaserin is being developed to treat a group of disorders known as developmental and epileptic encephalopathies (DEEs), including Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis ...

NICE estimates that there are around 1,400 people who will now be eligible for treatment with Fintepla, which was previously backed by NICE for Dravet syndrome, another severe epilepsy disorder ...

The global Oligonucleotide Synthesis Market is valued at USD 7.78 Billion in 2024 and is projected to reach a value of USD 21 ...

Chronic fatigue syndrome. Read the latest research news on chronic fatigue syndrome (CFS).

An estimated 10-15 percent of American adults suffer from irritable bowel syndrome (IBS). Proper diagnosis from a medical professional is important for getting effective treatment and relief.